2025-08-29 07:40:40
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Medicamen Biotech Ltd Q3 FY2023 consolidated profit at Rs. 3.77 crore
Posted On : 2023-02-11 17:24:43( TIMEZONE : IST )
MEDICAMEN BIOTECH LTD. has reported Consolidated financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 36.2105 crores during the period ended December 31, 2022 as compared to Rs. 34.0569 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 3.7702 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 3.6040 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 2.98 for the period ended December 31, 2022 as compared to Rs. 2.85 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹36.2105 crs | ₹34.0569 crs |  6.32% |
| Net Profit | ₹3.7702 crs | ₹3.6040 crs | 4.61% |
| EPS | ₹2.98 | ₹2.85 | 4.56% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.36.2105 crores during the period ended December 31, 2022 as compared to Rs.33.4684 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.3.7702 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.3.7785 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.2.98 for the period ended December 31, 2022 as compared to Rs.3.09 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹36.2105 crs | ₹33.4684 crs | 8.19% |
| Net Profit | ₹3.7702 crs | ₹3.7785 crs |  -0.22% |
| EPS | ₹2.98 | ₹3.09 | -3.56% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.104.3177 crores during the 9 Months period ended December 31, 2022 as compared to Rs.94.0739 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.10.9598 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.12.1517 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.8.66 for the 9 Months period ended December 31, 2022 as compared to Rs.9.95 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹104.3177 crs | ₹94.0739 crs | 10.89% |
| Net Profit | ₹10.9598 crs | ₹12.1517 crs | -9.81% |
| EPS | ₹8.66 | ₹9.95 | -12.96% |
Shares of MEDICAMEN BIOTECH LTD. was last trading in BSE at Rs. 731.20 as compared to the previous close of Rs. 760.20. The total number of shares traded during the day was 321 in over 105 trades.
The stock hit an intraday high of Rs. 758.95 and intraday low of 721.05. The net turnover during the day was Rs. 236994.00.
